https://exterapartners.com/bioinvent-announces-cancer-immunotherapy-research-collaboration-and-license-agreement-with-pfizer-and-issues-new-shares-to-pfizer/2017-07-24T19:39:43-04:00https://exterapartners.com/acer-therapeutics-obtains-exclusive-license-to-celiprolol-pivotal-clinical-data-from-ap-hp/2017-07-30T15:33:09-04:00https://exterapartners.com/catalyst-biosciences-announces-agreement-to-sell-nnr-asset/2017-07-24T19:29:27-04:00https://exterapartners.com/jacobs-stratasys-partner-to-advance-medical-3d-printing/2017-07-24T19:36:12-04:00https://exterapartners.com/stratasys-and-vital-images-partner-on-3d-printing/2017-07-24T19:29:49-04:00https://exterapartners.com/catalyst-biosciences-announces-agreement-to-sell-three-nnr-assets-to-attenua/2017-07-24T19:37:44-04:00https://exterapartners.com/censa-pharmaceuticals-inc-secures-series-a-financing-round-led-by-arkin-bio-ventures/2017-07-24T19:28:39-04:00https://exterapartners.com/acer-therapeutics-closes8-15-millionseries-bfinancing/2017-07-30T15:43:40-04:00https://exterapartners.com/dr-robert-parnell-joins-extera-partners-to-expand-its-diagnostics-advisory-capabilities/2017-07-24T18:27:56-04:00https://exterapartners.com/extera-partners-to-moderate-a-panel-at-the-mit-sloan-bioinnovations-conference-in-cambridge-massachusetts/2017-07-24T18:30:02-04:00https://exterapartners.com/cephalon-signs-option-agreement-to-acquire-bioassets-development-corporation/2017-07-24T18:31:54-04:00https://exterapartners.com/lothar-koob-joins-edge-medical-devices-board-of-directors/2017-07-24T18:32:50-04:00https://exterapartners.com/fda-clears-nexstims-navigated-brain-stimulation/2017-07-24T18:34:40-04:00https://exterapartners.com/extera-partners-adds-steven-berntiz-as-a-general-partner/2017-07-24T18:35:55-04:00https://exterapartners.com/lensar-appoints-chief-commercial-officer-and-chief-operating-officer/2017-07-24T18:37:17-04:00https://exterapartners.com/senior-executive-jean-pierre-capdevielle-joins-extera-partners/2017-07-24T18:38:21-04:00https://exterapartners.com/cephalon-exercises-its-option-to-acquire-bioassets-development-corporation/2017-07-24T18:39:04-04:00https://exterapartners.com/event-exteras-general-partner-a-panelist-at-mit-enterprise-forum-of-cambridge-event/2017-07-24T18:40:46-04:00https://exterapartners.com/xcounter-ab-announces-proposal-to-raise/2017-07-24T18:43:32-04:00https://exterapartners.com/free-webinar-accessing-the-european-medical-device-market-smart-approaches-to-ce-marking-and-effective-commercialization/2017-07-24T18:44:41-04:00https://exterapartners.com/extera-client-nexstim-attracts-additional-equity-financing-over-eur-13-million-now-raised-in-latest-round/2017-07-24T18:45:55-04:00https://exterapartners.com/advantagene-announces-spa-agreement-with-fda-to-launch-phase-3-trial-for-novel-vaccine-aimed-at-preventing-prostate-cancer-recurrence/2017-07-24T18:51:55-04:00https://exterapartners.com/senior-biopharma-business-development-executives-join-extera-partners/2017-07-24T18:52:43-04:00https://exterapartners.com/argos-therapeutics-files-registration-statement-for-proposed-initial-public-offering/2017-07-24T18:53:26-04:00https://exterapartners.com/extera-expands-its-orthopedic-pre-launch-planning-and-launch-management-services-in-europe/2017-07-24T18:54:32-04:00https://exterapartners.com/phosphagenics-to-proceed-with-twice-weekly-oxycodone-patch-development/2017-07-24T18:55:11-04:00https://exterapartners.com/topcon-and-lensar-announce-equity-investment-as-part-of-strategic-partnership/2017-07-24T18:55:54-04:00https://exterapartners.com/argos-therapeutics-announces-new-data-demonstrating-prolonged-overall-survival-in-a-phase-2-study-of-its-arcelis-immunotherapy-ags-003-in-combination-with-sunitinib-for-mrcc/2017-07-24T18:56:41-04:00https://exterapartners.com/lensar-raises-24-million-in-private-financing-to-support-commercial-launch-of-lensar-laser-system/2017-07-24T18:58:15-04:00https://exterapartners.com/argos-therapeutics-inc-raises-25-million-series-d-financing/2017-07-24T18:59:47-04:00https://exterapartners.com/lensar-laser-system/2017-07-24T19:00:43-04:00https://exterapartners.com/analogic-to-acquire-ultrasonix-medical-for-83m/2017-07-24T19:02:12-04:00https://exterapartners.com/lensar-laser-system-receives-fda-clearance-for-arcuate-incisions-in-cataract-surgery/2017-07-24T19:03:23-04:00https://exterapartners.com/argos-therapeutics-secures-42-5-million-financing-funds-pivotal-phase-3-adapt-trial-for-personalized-immunotherapy/2017-07-24T19:05:17-04:00https://exterapartners.com/lensar-secures-87-million-in-financing-to-support-market-expansion-of-its-laser-cataract-surgery-system/2017-07-24T19:06:19-04:00https://exterapartners.com/bioinvent-granted-us-patent-for-the-f-i-r-s-t-antibody-screening-technology/2017-07-24T19:07:15-04:00https://exterapartners.com/lensar-initiates-clinical-study-to-evaluate-lens-softening-effects-of-the-lensar-laser-system/2017-07-24T19:26:39-04:00https://exterapartners.com/argos-therapeutics-prices-initial-public-offering/2017-07-24T19:12:31-04:00https://exterapartners.com/painreform-seeks-new-deal-on-pain-management-product/2017-07-24T19:14:18-04:00https://exterapartners.com/real-imaging-receives-ce-mark-for-real-imager-8-breast-cancer-screening-system/2017-07-24T19:15:27-04:00https://exterapartners.com/lensar-inc-snags-8-million-for-laser-eye-surgery-systems/2017-07-24T19:16:18-04:00https://exterapartners.com/bioinvent-receives-another-milestone-payment-from-bayer-in-connection-with-start-of-a-phase-i-trial/2017-07-24T19:17:41-04:00https://exterapartners.com/lensar-partners-with-precision-eye-services-to-offer-full-service-mobile-laser-cataract-solution/2017-07-24T19:18:40-04:00https://exterapartners.com/models-from-3d-printers-help-doctors-perform-face-transplant-surger/2017-07-24T19:20:36-04:00https://exterapartners.com/bioinvents-bi-1206-antibody-to-enter-collaborative-phase-lll-trial-funded-and-conducted-by-cancer-research-uk-crt-and-llr/2017-07-24T19:21:24-04:00https://exterapartners.com/bioinvent-confirms-clinical-strategy-for-bi-505-and-plans-to-conduct-phase-iia-trial-in-multiple-myeloma-post-stem-cell-transplant-patients-in-the-us/2017-07-24T19:22:20-04:00https://exterapartners.com/janus-biotherapeutics-enters-collaboration-with-roche-in-autoimmune-diseases/2017-07-24T19:23:12-04:00https://exterapartners.com/alphaeon-pays-59-million-cash-for-lensar/2017-07-24T19:23:58-04:00https://exterapartners.com/novian-healths-novilase-shows-promising-results-for-breast-cancer-patients/2017-07-24T19:25:13-04:00https://exterapartners.com/position-available-at-extera-partners/2017-07-30T16:02:00-04:00https://exterapartners.com/walk-this-way-3d-printing-drives-new-advancements-in-foot-orthotics/2017-07-26T14:36:23-04:00https://exterapartners.com/acer-therapeutics-and-opexa-therapeutics-sign-merger-agreement/2017-07-30T15:48:07-04:00https://exterapartners.com/retrophin-and-censa-pharmaceuticals-enter-into-strategic-collaboration-to-advance-cnsa-001-for-the-treatment-of-phenylketonuria-pku/2018-01-16T05:58:50-05:00https://exterapartners.com/omega-funds-leads-35m-series-a-to-fuel-attenuas-cough-program-set-for-proof-of-concept-this-year/2018-05-31T16:37:11-04:00https://exterapartners.com/acer-therapeutics-expands-management-team-with-the-appointment-of-three-executives-and-one-new-key-hire/2018-05-31T16:48:06-04:00https://exterapartners.com/retrophin-initiates-pivotal-phase-3-clinical-trial-of-sparsentan-for-the-treatment-of-focal-segmental-glomerulosclerosis/2018-05-31T16:49:04-04:00https://exterapartners.com/retrophin-announces-pivotal-phase-3-fort-study-of-fosmetpantotenate-in-pkan-opens-enrollment-to-pediatric-patients/2018-07-27T20:13:13-04:00https://exterapartners.com/retrophin-reports-positive-long-term-data-from-open-label-extension-of-phase-2-duet-study-of-sparsentan-for-the-treatment-of-focal-segmental-glomerulosclerosis/2018-12-06T14:26:32-05:00https://exterapartners.com/acer-therapeutics-submits-nda-for-edsivo-for-the-treatment-of-veds/2018-12-06T14:27:09-05:00https://exterapartners.com/gamida-cell-announces-new-translational-data-for-nicord-to-be-presented-at-ash-2018-annual-meeting/2018-12-06T14:27:44-05:00https://exterapartners.com/censa-pharmaceuticals-completes-phase-i-study-and-initiates-enrollment-into-phase-ii-studies/2018-12-26T17:14:38-05:00https://exterapartners.com/acer-therapeutics-announces-in-license-of-osanetant-from-sanofi/2019-01-11T09:21:12-05:00https://exterapartners.com/acer-therapeutics-announces-fda-acceptance-of-nda-and-priority-review-for-edsivo-for-the-treatment-of-veds/2019-01-11T09:22:55-05:00https://exterapartners.com/retrophin-reports-fourth-quarter-and-full-year-2018-financial-results/2019-04-01T19:02:57-04:00https://exterapartners.com/acer-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-corporate-update/2019-04-01T19:08:17-04:00https://exterapartners.com/phase-2-open-label-trial-investigating-percutaneous-laser-ablation-for-treatment-of-early-stage-breast-cancer-mri-pathology-and-outcome-correlations/2019-07-31T14:57:24-04:00https://exterapartners.com/acer-therapeutics-announces-restructuring-and-update-on-pipeline-programs/2019-07-31T14:59:59-04:00https://exterapartners.com/retrophin-announces-fda-approval-of-thiola-ec-tiopronin-100mg-and-300mg-tablets-for-the-treatment-of-cystinuria/2019-07-31T15:08:50-04:00